Therefore, from the preliminary result, SPARCL1 could be considered a prognostic biomarker for advanced UTUC and further identification of the outcome of the clinical benefit of chemotherapy or radiation on patients with positive SPARCL1 UTUC needs further clinical trial for validation of its prognostic utility. Here, SPARCL1 is linked to renal pelvis/ureter urothelial carcinoma.